Oncogenesis - Table of Contents alert Volume 5, July 2016

TABLE OF CONTENTS Volume 5, July 2016 In this issue Original Articles Short Communications Sign up for e-alerts Web feed Advertisement Oncogenesis is an online-only, open access journal exploring the molecular basis of cancer and related phenomena. The journal seeks to promote diverse and integrated areas of molecular biology, cell biology, oncology, and genetics. Explore the benefits of submitting your next research article. Original Articles Top Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy S-M Kim, H Kim, M R Yun, H N Kang, K-H Pyo, H J Park, J M Lee, H M Choi, P Ellinghaus, M Ocker, S Paik, H R Kim and B C Cho Oncogenesis 2016 5: e241; 10.1038/oncsis.2016.48 Abstract | Full Text Nm23H1 mediates tumor invasion in esophageal squamous cell carcinoma by regulation of CLDN1 through the AKT signaling K-T Kuo, C-L Chen, T-Y Chou, C-T Yeh, W-H Lee and L-S Wang Oncogenesis 2016 5: e239; 10.1038/oncsis.2016.46 Abstract | Full Text TLR9 re-expression in cancer cells extends the S-phase and stabilizes p16INK4a protein expression P Parroche, G Roblot, F Le Calvez-Kelm, I Tout, M Marotel, M Malfroy, G Durand, J McKay, M Ainouze, C Carreira, O Allatif, A Traverse-Glehen, M Mendiola, J J Pozo-Kreilinger, C Caux, M Tommasino, N Goutagny and U A Hasan Oncogenesis 2016 5: e244; 10.1038/oncsis.2016.49 Abstract | Full Text Multi-omics landscapes of colorectal cancer subtypes discriminated by an individualized prognostic signature for 5-fluorouracil-based chemotherapy M Tong, W Zheng, H Li, X Li, L Ao, Y Shen, Q Liang, J Li, G Hong, H Yan, H Cai, M Li, Q Guan and Z Guo Oncogenesis 2016 5: e242; 10.1038/oncsis.2016.51 Abstract | Full Text Short Communications Top Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma T Kondo, S Ozawa, T Ikoma, X-Y Yang, K Kanamori, K Suzuki, H Iwabuchi, Y Maehata, C Miyamoto, T Taguchi, T Kiyono, E Kubota and R-I Hata Oncogenesis 2016 5: e240; 10.1038/oncsis.2016.43 Abstract | Full Text Comparative transcriptomic analysis reveals the oncogenic fusion protein PAX3-FOXO1 globally alters mRNA and miRNA to enhance myoblast invasion J M Loupe, P J Miller, B P Bonner, E C Maggi, J Vijayaraghavan, J S Crabtree, C M Taylor, J Zabaleta and A D Hollenbach Oncogenesis 2016 5: e246; 10.1038/oncsis.2016.53 Abstract | Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Oncogenesis. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.